Tempus AI to Recursion Pharmaceuticals: Extension to November 2029 of the 2023 data licence for Tempus's de-identified clinical and molecular records; discretionary fees are replaced by committed payments. Separately Recursion licenses its RNA foundation model TxFM to Tempus (no price in the release).
Committed payments of $42 million over the next three years, replacing discretionary fees that could have totalled $84 million over two years
Dated 21 Sep 2026Source checked 21 Sep 2026Basis: stated
In the source's own words
“In connection with the extension of the collaboration’s committed term, the parties agreed to amend the Annual License Fees payable under the original Master Agreement, replacing discretionary license fees potentially totaling $84 million over the next two years with committed payments totaling $42 million over the next three years.”
Where it was read
Tempus AI, checked 21 Sep 2026
What it is about
Figures it counts in
- 6The most disclosed deals with a dollar amount in any half-year